Biodexa's licensor emtora to announce phase 2 clinical trial results of erapa™ in familial adenomatous polyposis to be presented at prestigious 2024 digestive disease week annual meeting

April 30, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa's licensor emtora to announce phase 2 clinical trial results of erapa™ in familial adenomatous polyposis to be presented at prestigious 2024 digestive disease week annual meeting biodexa pharmaceuticals plc, (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that's its licensor emtora biosciences has announced that results of a phase 2 clinical trial of erapa in familial adenomatous polyposis (“fap”) are to be presented at the prestigious 2024 digestive disease week annual meeting in washington dc on may 18-21, 2024. carol burke, md, the principal investigator, will present the six month data (nct04230499) in an oral presentation at the meeting.
BDRX Ratings Summary
BDRX Quant Ranking